Erbitux for squamous cell cancer of unknown primary site

About 5% of all metastatic cancers come from the primary in an organ that cannot be securely identified. This may make assigning therapy difficult. The histology of the location may or may not give sufficient clues to where the cancer rose. The usually recommended approach is to use various stains to try to pinpoint the area of origin and then treat for that type of cancer. However, this is not always possible. When the primary site is not identified

Read more